Promising anti-tumor activity of novel costimulatory bispecific antibody regn7075 (egfrxcd28) in combination with libtayo® (cemiplimab) to be reported at asco

Oral presentation to highlight activity of regn7075 in combination with libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically proven unresponsive to immunotherapy
REGN Ratings Summary
REGN Quant Ranking